One of the advantages of being a dividend investor is that I invest in businesses that meet a certain qualitative and quantitative criteria. This allows me to focus on quality compounding machines with established track records. This discipline also allows me to avoid overpaying for those companies.
Even the best company in the world is not worth overpaying for. Another trait I have is patience – I am willing to sit on a stock for years, which reduces transaction costs and lets me take advantage of the maximum power of long-term compounding.
While everyone is complaining that the stock market is “high”, I went ahead and started looking for companies that are attractively valued today. I think that the following companies are worthy of being considered for your further research.
The companies include:
Medtronic PLC (MDT) manufactures and sells device-based medical therapies worldwide. This dividend champion has increased distributions for 39 years in a row. Over the past decade, Medtronic has raised its annual dividend at a rate of 14.30% per year. Currently, the stock is selling at 15.60 times forward earnings and yields 2.40%.
Hot Dividend Stocks To Invest In 2018: Ecolab Inc.(ECL)
- [By ]
Ecolab (ECL) : “That’s a terrific situation that I want you to buy more of if it comes down.”
PTC (PTC) : “Not my cup of tea but I understand it’s in the sweet spot of tech.”
- [By ]
3. Ecolab (NYSE: ECL)
This water, hygiene, and energy services company is being heavily bought by Bill Gates. Mr. Gates has purchased around a million shares across several transactions in the last 30 days. His purchase price was between $134.00 and $137.00 per share.
- [By ]
In the Lightning Round, Cramer was bullish on Goldman Sachs (GS) , Berkshire Hathaway (BRK.B) , Ecolab (ECL) , PTC (PTC) , Arista Networks (ANET) , U.S. Concrete (USCR) and Masco (MAS) .
Hot Dividend Stocks To Invest In 2018: Xcel Energy Inc.(XEL)
- [By Joseph Griffin]
Xcel Energy Inc (NYSE:XEL) has been assigned an average recommendation of “Buy” from the thirteen research firms that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $48.00.
- [By Maxx Chatsko]
The rise of wind power wouldn’t have been possible without two companies in particular, which combine to own 20.7 gigawatts of wind capacity, or about 24% of the country’s total. Investors wouldn’t be surprised to learn that clean energy provider NextEra Energy is one of the renewable energy stocks most important to American wind power.However, the relatively unheard of natural gas and electric utility Xcel Energy (NASDAQ:XEL) doesn’t seem to garner nearly the same level of attention. Overlooking it could be a mistake.
Hot Dividend Stocks To Invest In 2018: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Keith Speights]
I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.
- [By Brian Orelli]
The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn’t think a few months will really matter: “We don’t really feel that’s going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we’re very well prepared to be ready to launch following approval.”
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.